TickerTalks
Browse all tickers →
TickerTalks›$TMO
TMTMO

Thermo Fisher Scientific Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 6% YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (96 mentions/wk)
$TMO·$221B·Medical - Diagnostics & Research·Healthcare
$622.18-1.4%YTD-2.5%1Y+27.0%
Mentions · last 7 days
2026-08-21: 8 posts2026-08-22: 3 posts96+2%
Price updated 2d ago·X counts updated 8d ago
TMTMO
$TMOThermo Fisher Scientific Inc.
$622.18-1.35%96 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $TMO, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-08-30

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Life-science tools compounder finally testing resistance — the drawdown is behind it.

Thermo Fisher Scientific is the largest US life-sciences instrumentation, consumables, and services business, with real exposure to pharma/biotech R&D, diagnostics, and applied markets. Shares are basically flat YTD but +27% TTM at $622, roughly back to level after a ~25% drawdown.

  • Revenue and EPS are large and stable: quarterly revenue ran $10.86B / $11.12B / $12.22B / $11.01B, quarterly EPS at $4.28 / $4.28 / $5.22 / $4.44 — analysts model $47.8B and $25.01 EPS for the full year, so at $622 the stock is at roughly 25x forward, defensible for a compounder with this earnings visibility.
  • The lab-tools cohort has recovered: TMO/DHR/AVTR all catching a bid on 'best Q of the year' framing, with peers hitting multi-month highs — that's the mechanic that reprices the whole cohort when pharma/academic R&D comps get easier.
  • The product-cycle signal is durable: the EMPAD G2 electron detector for materials research is exactly the kind of leading-edge instrumentation that supports the analytical instruments segment, and continuing institutional accumulation (Beacon Pointe, Ausdal, Bank OZK) reinforces the setup.

An Oct 28 print that shows sequential revenue growth and any commentary on academic R&D or China exposure extends the coil; a soft China revenue print, an NIH-funding shock, or a specific consumables-margin compression is what caps the multiple.

Agrees with X sentimentX's bullish framing is well-anchored — the sandbagged Q2-guide setup, the DHR/AVTR cohort strength, and the easy pharma/academic R&D comps are all real supports for the fundamentals here.

What to watch: The Oct 28 Q3 print — segment revenue growth, gross margin, and any commentary on China exposure or NIH-funding trends. An academic R&D funding shock is the biggest external swing.

On the calendar: 2026-10-28 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-31

Bullish tape on Thermo Fisher and lab-tools peers. TMO is now roughly flat on the year after a ~25% drawdown, with peers DHR and AVTR hitting multi-month highs. Bulls frame this as the 'best Q of the year' for traditional-tools names on sandbagged Q2 guides and easy pharma/academic R&D comps. Dominant tone is thesis intact.

Read the AI verdict + X sentiment for $TMO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells life science instruments, reagents, and CDMO services to pharma, biotech, and academic research customers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $TMO.

Medical - Diagnostics & Research · Healthcare

Diagnostic testing volumes are normalizing post-COVID elevated baseline; liquid biopsy and genomic sequencing are the structural growth areas. Reimbursement rate changes (CMS updates) are the primary margin risk for established lab businesses.

What this means for $TMO

Partial — upstream oil & gas exposure ties to commodity price cycle; Thermo Fisher Scientific Inc.

Industry benchmark

21-name peer basket
+37.3%YTD
+81.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
25.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
7.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
17.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
13.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
39.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 23, 2026$6.03$5.72+5.4%
Q1 2026Apr 23, 2026$5.44$5.25+3.6%
Q4 2025Jan 29, 2026$6.57$6.45+1.9%
Q3 2025Oct 22, 2025$5.79$5.50+5.3%
Next earningsWed, Oct 28·consensus EPS $6.40

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$11.0B+6.2%40.7%16.9%$4.44$816.0M
Q4 FY25$12.2B+7.2%38.0%18.8%$5.22$3.0B
Q3 FY25$11.1B+4.9%41.8%17.5%$4.28$1.8B
Q2 FY25$10.9B+3.0%37.3%17.7%$4.28$1.1B

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$47.8B$47.6B – $47.9B$25.01$24.79 – $25.1819
FY27$50.3B$48.8B – $51.0B$27.31$26.37 – $28.0220
FY28$53.4B$52.5B – $54.4B$30.16$27.43 – $32.5116
FY29$56.6B$55.8B – $57.2B$33.96$33.38 – $34.4015
FY30$58.5B$57.7B – $59.1B$38.14$37.49 – $38.6415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+16.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 370.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.855-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 24Marc N CasperCEO275 sh$172KSellAug 21Marc N CasperCEO10.0K sh$6.3MSellAug 20Marc N CasperCEO10.0K sh$6.3MSellAug 19Lisa P. BrittSr. VP and Chief HR Officer11.4K sh$7.0MSellAug 11Michael D ShaferPresident14.3K sh$8.6MSellAug 7Joseph R. HolmesVP & Chief Accounting Officer420 sh$246KSellAug 7Marc N CasperCEO268 sh$157KSellAug 6Lisa P. BrittSr. VP and Chief HR Officer5.8K sh$3.4MSellAug 6Marc N CasperCEO8.9K sh$5.1MSellAug 5Marc N CasperCEO15.0K sh$8.6M
1–10 of 15
+ 34 other (20 awards · 12 exempts · 2 inkinds) in window

See when $TMO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 268-K — Item 5.07: Shareholder vote
AI summary

Thermo Fisher Scientific held its Annual Meeting on May 20, 2026. Director election results (partial—excerpt truncated): Marc N. Casper (294M for, 20.5M against), Nelson J. Chai (293M for, 21.6M against), Ruby R. Chandy (312M for, 2.5M against), and C. Martin Harris (285.5M for—full tally cut off). Casper and Chai received modestly elevated against votes (~6-7%) but were comfortably elected. Routine annual meeting filing.

3New insider — initial holdingsMar 103
+ 13 other (3 proxys · 2 10-Qs · 2 earnings 8-Ks · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

37,709 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Beacon Pointe Advisors LLCdefenseworld.net·2d agoAusdal Financial Partners Inc. Makes New $456,000 Investment in Thermo Fisher Scientific Inc. $TMOdefenseworld.net·3d agoBank OZK Takes $1.10 Million Position in Thermo Fisher Scientific Inc. $TMOdefenseworld.net·3d agoThermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Researchbusinesswire.com·4d agoDelta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC's ‘Final Trades'benzinga.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$TWST$PSNL$A$ILMN$NTRA$GH$DHR
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport